{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/theophylline/","result":{"pageContext":{"chapter":{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline","depth":2,"htmlHeader":"<!-- begin field a3340918-0a5e-4d74-8134-09cc3ef5ce76 --><h2>Theophylline</h2><!-- end field a3340918-0a5e-4d74-8134-09cc3ef5ce76 -->","summary":"","htmlStringContent":"<!-- begin item 7a10ce13-da6a-46f7-b94c-10e28867240c --><!-- end item 7a10ce13-da6a-46f7-b94c-10e28867240c -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2097a561-e40a-5e4b-b474-531bae5f09bd","slug":"brand-names","fullItemName":"Brand names","depth":3,"htmlHeader":"<!-- begin field 801cc25d-d172-4694-94eb-03cc2d6998d7 --><h3>How should theophylline be prescribed?</h3><!-- end field 801cc25d-d172-4694-94eb-03cc2d6998d7 -->","summary":"","htmlStringContent":"<!-- begin item 759b67c1-477d-4766-bfb6-23ff84e14143 --><!-- begin field 79f9ffac-8030-47a9-879f-4be6cdb51383 --><ul><li>Prescribe theophylline by brand name as there are bioavailablility differences between brands — if discharged from hospital on theophylline the brand of on which they were stabilized as an inpatient should be maintained.<ul><li>Plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. Plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of theophylline are important because the toxic dose is close to the therapeutic dose.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>]</p><!-- end field 79f9ffac-8030-47a9-879f-4be6cdb51383 --><!-- end item 759b67c1-477d-4766-bfb6-23ff84e14143 -->","subChapters":[]},{"id":"763e69f4-a3a8-564b-8d8d-09e8b2e27d93","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field ce33a1a4-a9c3-4293-93f0-4d5b1c6cbd81 --><h3>What dose of theophylline should I prescribe for COPD?</h3><!-- end field ce33a1a4-a9c3-4293-93f0-4d5b1c6cbd81 -->","summary":"","htmlStringContent":"<!-- begin item bb5f9da4-e52b-4af0-8f4b-d2150f2d4717 --><!-- begin field 40625f76-1e60-422a-8390-eac40dba1001 --><ul><li>Theophylline<ul><li>Nuelin SA® modified release tablets:<ul><li>Nuelin SA® 175 tablets — for reversible airways obstruction, 175 mg twice daily, increasing to 350 mg if necessary.</li><li>Nuelin SA® 250 tablets — for reversible airways obstruction, 250 mg twice daily, increasing to 500 mg if necessary.</li></ul></li><li>Slo-Phyllin® modified-release capsules — for reversible airways obstruction, 250 mg to 500 mg every 12 hours, titrate from lowest dose depending on response.</li><li>Uniphyllin Continus® modified-release tablets — for reversible airways obstruction, 200 mg every 12 hours. This may be titrated to either 300 mg or 400 mg according to response.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017b</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018q</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field 40625f76-1e60-422a-8390-eac40dba1001 --><!-- end item bb5f9da4-e52b-4af0-8f4b-d2150f2d4717 -->","subChapters":[]},{"id":"3445922b-4527-5084-a296-ff4550baa525","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 70a62c57-6784-4cb7-b9fd-3c82a07cab45 --><h3>How should theophylline be monitored?</h3><!-- end field 70a62c57-6784-4cb7-b9fd-3c82a07cab45 -->","summary":"","htmlStringContent":"<!-- begin item 0d864a14-4969-4f70-b53d-eb9ca03cf6a5 --><!-- begin field 407b88d9-744f-4562-a526-3cf35fc7be83 --><ul><li><strong>Before starting theophylline, check:</strong><ul><li>Urea and electrolyte levels (paying particular attention to potassium levels).</li><li>Liver function.</li></ul></li><li><strong>Check drug plasma levels:</strong><ul><li>Five days after starting oral treatment.</li><li>Routinely every 6–12 months. Check more regularly in older people or those with heart failure or hepatic impairment.</li><li>At least 3 days after any dose adjustments.</li><li>If the person experiences adverse effects that may suggest toxicity (such as nausea, vomiting, tremor or palpitations).</li><li>If an enzyme-inhibiting drug (such as erythromycin, clarithromycin, allopurinol, or cimetidine) is prescribed (raises plasma levels) or if an enzyme-inducing drug (such as carbamazepine, rifampicin, or St John's Wort) is prescribed (lowers plasma levels).</li><li>If the person starts or stops smoking — a dose adjustment may be needed because tobacco can lower the plasma levels of theophylline.</li></ul></li><li><strong>Plasma potassium concentrations may be reduced by beta-2 agonists, corticosteroids, and diuretics. This effect may be potentiated by theophylline</strong>. Check potassium levels regularly in:<ul><li>People taking beta-2 agonists, corticosteroids, or diuretics.</li><li>People who are hypoxic — theophylline can potentiate hypokalaemia resulting from hypoxia.</li></ul></li><li><strong>Careful monitoring is recommended for patients with congestive heart failure, chronic alcoholism, hepatic dysfunction, or viral infections — </strong>they may have a lower clearance of theophylline, which could lead to higher than normal plasma levels.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">SPS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field 407b88d9-744f-4562-a526-3cf35fc7be83 --><!-- end item 0d864a14-4969-4f70-b53d-eb9ca03cf6a5 -->","subChapters":[]},{"id":"b5952642-9d6b-544e-b845-12758a9c7acf","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 1d647b58-c7ab-499a-a440-db7c777ae729 --><h3>When should theophylline be used with caution?</h3><!-- end field 1d647b58-c7ab-499a-a440-db7c777ae729 -->","summary":"","htmlStringContent":"<!-- begin item 46e1421a-e426-4938-954f-83d1942c6937 --><!-- begin field 7af959f4-bce3-42f0-b49a-d7be4ee6eb79 --><ul><li><strong>Do not use theophylline in people with:</strong><ul><li>Recent myocardial infarction.</li><li>Acute tachycardia.</li><li>Porphyria.</li></ul></li><li><strong>Use theophylline with caution in people with:</strong><ul><li>Cardiovascular disease, including cardiac arrhythmias and heart failure.</li><li>Hepatic impairment.</li><li>Hyperkalaemia risk — for more information, see the section on monitoring.</li><li>Hypertension.</li><li>Hyperthyroidism and hypothyroidism.</li><li>Peptic ulcers.</li><li>Fever — decreases the clearance of theophylline.</li><li>Epilepsy – manufacturer recommends avoid.</li></ul></li><li>In addition, particular caution needs to be observed in older people due to differences in pharmacokinetics, increased likelihood of comorbidities, and the use of other medications.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017b</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018q</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] </p><!-- end field 7af959f4-bce3-42f0-b49a-d7be4ee6eb79 --><!-- end item 46e1421a-e426-4938-954f-83d1942c6937 -->","subChapters":[]},{"id":"713daa8f-a520-50de-af86-4d244abac1a7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f20ff59f-c0e6-469c-8861-d23a39dc2550 --><h3>What important adverse effects are associated with theophylline?</h3><!-- end field f20ff59f-c0e6-469c-8861-d23a39dc2550 -->","summary":"","htmlStringContent":"<!-- begin item c1a1c9e2-0e18-41d3-aa85-4f13863f016e --><!-- begin field 9735ddc2-2c2a-4cb7-98ac-886883c4912f --><ul><li>The adverse effects of theophylline include:<ul><li>Gastrointestinal disorders such as nausea, vomiting, gastro-oesophageal reflux.</li><li>Neurological disorders such as tremor, headache, dizziness, central nervous system stimulation, insomnia, and convulsion (rare).</li><li>Psychiatric disorders such as anxiety.</li><li>Metabolic and electrolyte disorders such as hypokalaemia, hyperuricaemia, hyperglycaemia and hyperuricaemia.</li><li>Cardiovascular disorders such as palpitations, arrhythmias and hypotension.</li><li>Skin reactions.</li></ul></li><li>Potentially serious hypokalaemia may result from beta-2 agonist therapy.</li><li>Adverse effects can occur with plasma theophylline concentrations of 10 mg/L to 20 mg/L. However, a plasma concentration in this range is required in most people to achieve a satisfactory clinical effect.</li><li>Both the frequency and severity of adverse effects increase when plasma concentrations of aminophylline or theophylline are above 20 mg/L.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 9735ddc2-2c2a-4cb7-98ac-886883c4912f --><!-- end item c1a1c9e2-0e18-41d3-aa85-4f13863f016e -->","subChapters":[]},{"id":"e31d1ae6-783f-5330-a575-d29b7e6e1d02","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2dd6c210-1cc6-4169-948a-266c0f2bd200 --><h3>What are the key drug interactions with theophylline?</h3><!-- end field 2dd6c210-1cc6-4169-948a-266c0f2bd200 -->","summary":"","htmlStringContent":"<!-- begin item 40e478fe-5c07-40c6-898a-9b1c74cb356f --><!-- begin field 611c22c4-c2d2-4ea5-8dbb-61e821bb4d19 --><ul><li><strong>Theophylline interacts with many drugs including:</strong><ul><li>Beta-2 agonists, corticosteroids, diuretics — potentially serious hypokalaemia may result from beta-2 agonist therapy.<ul><li>Check serum potassium levels regularly.</li></ul></li><li>Lithium — excretion of lithium may be potentiated.<ul><li>Check plasma lithium levels and alter dose if necessary.</li></ul></li><li>Fluvoxamine — can raise the plasma level of theophylline.<ul><li>Avoid concomitant use if possible, or halve the dose and monitor plasma levels.</li></ul></li><li>Digoxin — increased risk of digoxin toxicity.</li><li>Other xanthine containing medications — avoid concomitant administration.</li></ul></li><li><strong>Plasma levels of theophylline can be altered by concomitant use with</strong> liver enzyme-inhibiting drugs such as verapamil, ciprofloxacin, fluconazole, erythromycin, clarithromycin, allopurinol, or cimetidine, or liver enzyme-inducing drugs such as primidone, phenobarbital, carbamazepine, phenytoin, ritonavir, rifampicin, or St John's Wort.</li><li><strong>Influenza vaccine — </strong>there are conflicting reports concerning the potentiation of theophylline by influenza vaccine, interaction may occur resulting in increased serum theophylline levels.</li><li><strong>The person should be made aware that:</strong><ul><li>Over-the-counter cough and decongestant preparations that contain theophylline should be avoided.</li><li>Coffee increases the effect of theophylline.</li></ul></li><li><strong>Due to the many interactions of theophylline, monitoring of serum theophylline concentrations is recommended during long-term use with other drugs.</strong><ul><li>For a detailed list of interactions, see the BNF and Summary of Product Characteristics.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>]</p><!-- end field 611c22c4-c2d2-4ea5-8dbb-61e821bb4d19 --><!-- end item 40e478fe-5c07-40c6-898a-9b1c74cb356f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}